"NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO

Peritoneal Dialysis International

Volumn 32, Issue 1, 2012, Pages 45-54

  le Poole, Caatje Y ^a,b   van Ittersum, Frans J ^b   Valentijn, Rob M ^a   Teerlink, Tom ^c   Lindholm, Bengt ^d   Ter Wee, Piet M ^b   Schalkwijk, Casper G ^c  

^a Red Cross Hospital Den Haag   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Advanced glycation end products; Amino acids; Glucose degradation products; Icodextrin

Indexed keywords

3 DEOXYGLUCOSONE; 6 N CARBOXYETHYLLYSINE; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMINO ACID; BICARBONATE; DIALYSIS FLUID; GLUCOSE; ICODEXTRIN; LACTIC ACID; METHYLGLYOXAL; PENTOSIDINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; LIPID BLOOD LEVEL; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ALLERGY; THERAPY EFFECT;

ARGININE; BICARBONATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DEOXYGLUCOSE; DIALYSIS SOLUTIONS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GLUCANS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LACTATES; LYSINE; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONEUM; PROSPECTIVE STUDIES; PYRUVALDEHYDE;

EID: 84856646340     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00101     Document Type: Article

References (38)

1. Gokal R, Mallick NP. Peritoneal dialysis. Lancet 1999; 353:823-8
2. Gokal R, Oreopoulos DG. Is long-term technique survival on continuous ambulatory peritoneal dialysis possible? Perit Dial Int 1996; 16:553-5
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am JKidney Dis 1998; 32(Suppl 3):S112-19.
4. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. JAm Soc Nephrol 2002; 13:1918-27.
5. Suliman ME, Heimbürger O, Bárány P, Anderstam B, Pecoits-Filho R, Rodríguez Ayala E, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. JAm Soc Nephrol 2003; 14:1614-22.
6. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995; 46:223-34.
7. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999; 19:325-33.
8. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61:375-86.
9. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. JAm Soc Nephrol 1996; 7:1198-206.
10. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
11. Erixon M, Wieslander A, Lindén T, Carlsson O, Jönsson JA, Simonsen O, et al. 3,4-Dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma. Perit Dial Int 2009; 29(Suppl 2):S28-31.
12. Erixon M, Wieslander A, Lindén T, Carlsson O, Jönsson JA, Simonsen O, et al. 3,4-DGE in peritoneal dialysis fluids cannot be found in plasma after infusion into the peritoneal cavity. Perit Dial Int 2008; 28:277-82.
13. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
14. Miyata T, Kurokawa K, van Ypersele de Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. JAm Soc Nephrol 2000; 11:1744-52.
15. Schalkwijk CG, ter Wee PM, Teerlink T. Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids. Perit Dial Int 2000; 20:796-8.
16. le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM. Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 2004; 20:170-6.
17. le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM. Clinical effects of a PD regimen low in glucose in new PD patients: a randomized cross-over study. Perit Dial Int 2005; 25(Suppl 3):S64-7.
18. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41:153-9.
19. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999; 55:389-99.
20. Wilker SC, Chellan P, Arnold BM, Nagaraj RH. Chromatographic quantification of argpyrimidine, a methylglyoxal-derived product in tissue proteins: comparison with pentosidine. Anal Biochem 2001; 290:353-8.
21. Friedlander MA, Wu YC, Elgawish A, Monnier VM. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. JClin Invest 1996; 97:728-35.
22. Inagi R, Miyata T. Oxidative protein damage with carbohydrates and lipids in uremia: "carbonyl stress." Blood Purif 1999; 17:95-8.
23. Teerlink T, Barto R, Ten Brink HJ, Schalkwijk CG. Measurement of Nε-(carboxymethyl)lysine and Nε-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004; 50:1222-8.
24. Twisk JW. Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis. Eur JEpidemiol 2004; 19:769-76.
25. Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier MA, et al. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005; 365:588-94.
26. Boer WH, Vos PF, Fieren MW. Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis. Perit Dial Int 2003; 23:33-8.
27. Thornalley PJ, Yurek-George A, Argirov OK. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. Biochem Pharmacol 2000; 60:55-65.
28. Konings CJ, Schalkwijk CG, van der Sande FM, Leunissen KM, Kooman JP. Influence of icodextrin on plasma and dialysate levels of Nε-(carboxymethyl)lysine and Nε-(carboxyethyl)lysine. Perit Dial Int 2005; 25:591-5.
29. Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. Nε-(Carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J1997; 324:565-70.
30. van de Kerkhof J, Schalkwijk CG, Konings CJ, Cheriex EC, van der Sande FM, Scheffer PG, et al. Nε-(Carboxymethyl)lysine, Nε-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19:910-16.
31. Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, et al. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 2000; 58:2518-24.
32. Kusunoki H, Miyata S, Ohara T, Liu BF, Uriuhara A, Kojima H, et al. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 2003; 26:1889-94.
33. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl JMed 1986; 314:403-8.
34. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl JMed 1988; 318:1315-21.
35. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. JHypertens 2003; 21:3-12.
36. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93:1159-69.
37. McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, et al. Tissue-advanced glycation end product concentration in dialysis patients. Clin JAm Soc Nephrol 2010; 5:51-5.
38. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62:301-10.